Allist Pharmaceuticals

Allist Pharmaceuticals initiates trial for JAB-21822 in NSCLC with KRAS p.G12C and STK11 mutations

Allist Pharmaceuticals has initiated a clinical trial for JAB-21822, focusing on patients with advanced or metastatic non-small cell lung cancer (NSCLC) characterized by KRAS p.G12C and STK11 co-mutations.

Phase 1b Study of Furmonertinib in NSCLC Patients with Exon 20 Insertion Mutation

Allist Pharmaceuticals is conducting a phase 1b trial to evaluate Furmonertinib Mesilate in 30 NSCLC patients with EGFR exon 20 insertion mutations, focusing on efficacy and safety.

Phase III Trial of Firmonertinib vs Platinum Chemotherapy in NSCLC with EGFR Mutations